India 'refuses' to progress Novartis Galvumet patent application
This article was originally published in Scrip
Executive Summary
The Indian patent office has declined to "proceed further" with Novartis' application for vildagliptin and metformin in a single formulation (Galvumet) citing lack of inventive step and objections around the "sufficiency of disclosure".